HHSN261201200021I/HHSN26100007Preclinical In Vitro and In Vivo Development Assays for Cancer Preventative Reagent. Project Title: Effect of Bazedoxifene Either Alone or in Combination with an Aroma

HHSN261201200021I/HHSN26100007癌症预防试剂的临床前体外和体内开发测定。

• 批准号: 8945265
• 负责人: CLINTON GRUBBS
• 金额: $ 54.51万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-12 至 2016-09-11
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8945265
• 关键词: Animals; Biological Markers; Chemopreventive Agent; Contractor; Contracts; Data; Dose; Experimental Models; Female; Generations; Histologic; In Vitro; Lesion; Malignant Neoplasms; Mammary Neoplasms; Mammary Tumorigenesis; Maximum Tolerated Dose; Methodology; Methylnitrosourea; Molecular Target; Nitrosourea Compounds; Protocols documentation; Reagent; Route; Selective Estrogen Receptor Modulators; Signal Pathway; Signal Transduction; Sprague-Dawley Rats; Testing; Time; Tissue Banks; animal age group; assay development; design; in vivo; prevent; tumor

This contract is to assess the new third-generation SERM, Bazedoxifene, alone and in combination with CE and/or an AI, to prevent mammary carcinogenesis induced in virgin female Sprague-Dawley rats by N-methyl-N-nitrosourea (MNU). The tasks will involve optimizing the dose and timing of BZA administration, and PK profile of BZA in combination with the AI.

本合同旨在评估新的第三代SERM（巴多昔芬）单独使用以及与CE和/或AI联合使用预防N-甲基-N-亚硝基脲（MNU）在未交配雌性Sprague-Dawley大鼠中诱导的乳腺癌发生。这些任务将涉及优化BZA给药的剂量和时间，以及BZA与AI结合的PK特征。